TruSight™ Oncology Comprehensive
TruSight Oncology Comprehensive is the first US FDA–approved, distributable comprehensive genomic profiling (CGP) in vitro diagnotics (IVD) test with pan-cancer companion diagnostic (CDx) claims, helping democratize access to potentially life-saving diagnostic testing.
Go from sample to report in just 4 to 5 days, optimizing your time to go-live and empowering you to generate test results quickly and accurately.
Long Description
TruSight Oncology Comprehensive (TSO Comprehensive) consolidates numerous individual tests into a single panel, minimizing the amount of sample needed and maximizing the ability to potentially identify an actionable biomarker for better patient outcomes.
In addition, as a kitted solution, it enables testing in house and closer to the patient, potentially reducing the turnaround time to result and empowering pathologists to play a more active role on the patient care team. Go from sample to report in just 4 to 5 days.
TSO Comprehensive is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the listed targeted therapies, in accordance with the approved therapeutic product labeling.
High Resolution Image
Small Image
Large Image
Category Product Showcase